Constellation Stock Hits New 52-Week High (STZ)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Constellation Brands (NYSE: STZ) hit a new 52-week high Tuesday as it is currently trading at $33.24, above its previous 52-week high of $33.23 with 1.6 million shares traded as of 12:39 p.m. ET. Average volume has been 3.2 million shares over the past 30 days.

Constellation has a market cap of $5.07 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 59.4% year to date as of the close of trading on Friday.

Constellation Brands, Inc. produces and markets beverage alcohol in the United States and internationally. The company has a P/E ratio of 15.2, equal to the average food & beverage industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Constellation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Constellation Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing